Abstract B025: Follow up after a positive HPV test result: Results from the PRESTIS study

Abstract Background: HPV self-collection was recently FDA-approved for cervical cancer screening. In the PRESTIS trial, we recently demonstrated a 2.5-fold increase in screening participation among underscreened women in a public safety net health system who received a mailed at-home HPV self- collection kit compared to those who received a standard telephone reminder. However, receipt of clinical follow up among participants with a positive HPV test has not been described. Methods: We used data from the PRESTIS randomized clinical trial (n=2,464). Bilingual (English/Spanish) patient navigation was provided to assist participants with a positive HPV test result with scheduling and attending follow up appointments (colposcopy if positive for HPV 16 or 18; triage Pap test if positive for other high-risk types). We summarized receipt of follow-up care in regard to timeliness and demographic characteristics using descriptive and bivariable statistics. Results: Among participants with a positive HPV test result (n=90), 83.3% scheduled a follow up test and 70.0% completed clinical follow up. Among those who attended follow up (n=63), 65.1% received timely follow up within 3 months of their test result; 15.9% and 19.1%, respectively, received follow up between 3-6 months and after 6 months of their test result. Patients who needed colposcopy (n=16) had a higher proportion of follow up (93.8%) compared to those triaged to Pap testing (64.9% of n= 74). Fewer non-Hispanic Black participants (58.6%) attended clinical follow up compared to Hispanic (76.4%) and non-Hispanic White (66.7%) participants. A higher proportion of those with county-funded financial assistance (75.5%) and commercial insurance (65.2%) attended follow up compared with those covered by Medicaid, Medicare, or other insurance plans (53.9%). Conclusions: While mailed self-collection kits can increase cervical screening participation, almost one-third of participants with a positive HPV test did not complete clinical follow-up, despite patient navigation. This underscores the need for additional strategies to address barriers among screen-positive patients to ensure they receive timely and appropriate follow-up care. Citation Format: Graciela Nogueras, Trisha Amboree, Susan Parker, Antonia Marinoni, Matthew Anderson, Susan Hilsenbeck, Shaun Bulsara, Maria Daheri, Maria Jibaja-Weiss, Kathleen Schmeler, Ashish Deshmukh, Elizabeth Chiao, Michael Scheurer, Jane Montealegre. Follow up after a positive HPV test result: Results from the PRESTIS study [abstract]. In: Proceedings of the 18th AACR Conference on the Science of Cancer Health Disparities; 2025 Sep 18-21; Baltimore, MD. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2025;34(9 Suppl):Abstract nr B025.

Authors

Institutions

Publication Details

Journal
Cancer Epidemiology Biomarkers & Prevention
Published
2025-09-18
DOI
https://doi.org/10.1158/1538-7755.disp25-b025
Primary Topic
Cervical Cancer and HPV Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract B025: Follow up after a positive HPV test result: Results from the PRESTIS study

Maria Jibaja‐Weiss, Ashish A. Deshmukh, Alessandra Marinoni, Michael E. Scheurer et al.
Cancer Epidemiology Biomarkers & Prevention
Cervical Cancer and HPV Research
article

Abstract B025: Follow up after a positive HPV test result: Results from the PRESTIS study

Maria Jibaja‐Weiss, Ashish A. Deshmukh, Alessandra Marinoni, Michael E. Scheurer, Shaun Bulsara, Susan Parker, Maria Daheri, Elizabeth Y. Chiao, Matthew L. Anderson, Trisha L. Amboree, Susan Galloway Hilsenbeck, Jane R. Montealegre, Kathleen M. Schmeler, Graciela M. Nogueras
article en

Abstract

Abstract Background: HPV self-collection was recently FDA-approved for cervical cancer screening. In the PRESTIS trial, we recently demonstrated a 2.5-fold increase in screening participation among underscreened women in a public safety net health system who received a mailed at-home HPV self- collection kit compared to those who received a standard telephone reminder. However, receipt of clinical follow up among participants with a positive HPV test has not been described. Methods: We used data from the PRESTIS randomized clinical trial (n=2,464). Bilingual (English/Spanish) patient navigation was provided to assist participants with a positive HPV test result with scheduling and attending follow up appointments (colposcopy if positive for HPV 16 or 18; triage Pap test if positive for other high-risk types). We summarized receipt of follow-up care in regard to timeliness and demographic characteristics using descriptive and bivariable statistics. Results: Among participants with a positive HPV test result (n=90), 83.3% scheduled a follow up test and 70.0% completed clinical follow up. Among those who attended follow up (n=63), 65.1% received timely follow up within 3 months of their test result; 15.9% and 19.1%, respectively, received follow up between 3-6 months and after 6 months of their test result. Patients who needed colposcopy (n=16) had a higher proportion of follow up (93.8%) compared to those triaged to Pap testing (64.9% of n= 74). Fewer non-Hispanic Black participants (58.6%) attended clinical follow up compared to Hispanic (76.4%) and non-Hispanic White (66.7%) participants. A higher proportion of those with county-funded financial assistance (75.5%) and commercial insurance (65.2%) attended follow up compared with those covered by Medicaid, Medicare, or other insurance plans (53.9%). Conclusions: While mailed self-collection kits can increase cervical screening participation, almost one-third of participants with a positive HPV test did not complete clinical follow-up, despite patient navigation. This underscores the need for additional strategies to address barriers among screen-positive patients to ensure they receive timely and appropriate follow-up care. Citation Format: Graciela Nogueras, Trisha Amboree, Susan Parker, Antonia Marinoni, Matthew Anderson, Susan Hilsenbeck, Shaun Bulsara, Maria Daheri, Maria Jibaja-Weiss, Kathleen Schmeler, Ashish Deshmukh, Elizabeth Chiao, Michael Scheurer, Jane Montealegre. Follow up after a positive HPV test result: Results from the PRESTIS study [abstract]. In: Proceedings of the 18th AACR Conference on the Science of Cancer Health Disparities; 2025 Sep 18-21; Baltimore, MD. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2025;34(9 Suppl):Abstract nr B025.

Cancer Epidemiology Biomarkers & PreventionVol. 34(9_Supplement)
The University of Texas MD Anderson Cancer Center (US), Emory University (US), Medical University of South Carolina (US), Baylor College of Medicine (US), University of South Florida (US), Harris Health System (US)
Openalex Percentile: Top 66%
Cervical Cancer and HPV Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.